PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.
PET/CT-guided preoperative treatment strategy
localised oesophago-gastric junction adenocarcinoma
metabolic imaging
non-responders
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
09
2021
accepted:
15
11
2021
entrez:
17
1
2022
pubmed:
18
1
2022
medline:
18
1
2022
Statut:
epublish
Résumé
Perioperative chemotherapy is a recommended treatment approach for localised oesophago-gastric junction adenocarcinoma, but not all patients respond to neoadjuvant chemotherapy. Early identification of non-responders and treatment adaptation in the preoperative period could improve outcomes. GastroPET is a national, multicentre phase II trial evaluating a Patients with locally advanced oesophago-gastric junction adenocarcinoma (Siewert I - III) stage Ib-IIIc underwent baseline 18FDG-PET/CT scanning and re-evaluation after 14 days of oxaliplatinum-5FU-(docetaxel) chemotherapy. Responders were defined by a ⩾ 35% decrease in tumour FDG standardised uptake value (SUV) A total of 64 patients received baseline and sequential 14-day 18FDG-PET/CT scanning. And, 63 were allocated to the respective treatment arm according to PET-response [35 (56%) responders and 28 (44%) non-responders]. The concordance of local Local and central FDG-SUV quantification and PET-response assessment showed high concordance. This confirms the accuracy of a PET-response-guided treatment algorithm for locally advanced oesophago-gastric junction cancer in a multicenter setting. Preoperative treatment adaptation revealed feasible and safe for patients.
Sections du résumé
BACKGROUND
BACKGROUND
Perioperative chemotherapy is a recommended treatment approach for localised oesophago-gastric junction adenocarcinoma, but not all patients respond to neoadjuvant chemotherapy. Early identification of non-responders and treatment adaptation in the preoperative period could improve outcomes. GastroPET is a national, multicentre phase II trial evaluating a
METHODS
METHODS
Patients with locally advanced oesophago-gastric junction adenocarcinoma (Siewert I - III) stage Ib-IIIc underwent baseline 18FDG-PET/CT scanning and re-evaluation after 14 days of oxaliplatinum-5FU-(docetaxel) chemotherapy. Responders were defined by a ⩾ 35% decrease in tumour FDG standardised uptake value (SUV)
RESULTS
RESULTS
A total of 64 patients received baseline and sequential 14-day 18FDG-PET/CT scanning. And, 63 were allocated to the respective treatment arm according to PET-response [35 (56%) responders and 28 (44%) non-responders]. The concordance of local
CONCLUSION
CONCLUSIONS
Local and central FDG-SUV quantification and PET-response assessment showed high concordance. This confirms the accuracy of a PET-response-guided treatment algorithm for locally advanced oesophago-gastric junction cancer in a multicenter setting. Preoperative treatment adaptation revealed feasible and safe for patients.
Identifiants
pubmed: 35035533
doi: 10.1177/17588359211065153
pii: 10.1177_17588359211065153
pmc: PMC8753528
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359211065153Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Références
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Lancet Oncol. 2007 Sep;8(9):797-805
pubmed: 17693134
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
PET Clin. 2015 Apr;10(2):197-205
pubmed: 25829086
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
J Nucl Med. 2011 Aug;52(8):1189-96
pubmed: 21764790
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Oncol. 2016 Apr;27(4):660-7
pubmed: 26782957
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Clin Cancer Res. 2008 Apr 1;14(7):2012-8
pubmed: 18381939
BMC Cancer. 2016 Jul 19;16:503
pubmed: 27435280
Br J Surg. 2018 Mar;105(4):419-428
pubmed: 29417984
World J Surg. 2004 Mar;28(3):247-53
pubmed: 14961197
Ann Oncol. 2020 Feb;31(2):236-245
pubmed: 31959340
Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95
pubmed: 12552348
Eur J Cancer. 2022 Nov;175:99-106
pubmed: 36099671
Ann Surg Oncol. 2017 Aug;24(8):2252-2258
pubmed: 28337660
J Clin Oncol. 2011 Dec 1;29(34):4555-60
pubmed: 22025151
Ann Oncol. 2016 Sep;27(suppl 5):v50-v57
pubmed: 27664261
Dig Surg. 2018;35(3):196-203
pubmed: 28697493
J Clin Oncol. 2008 Mar 1;26(7):1086-92
pubmed: 18309943
Front Oncol. 2020 Jan 30;9:1320
pubmed: 32083013
Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):525-9
pubmed: 11914891
J Clin Oncol. 2021 Sep 1;39(25):2803-2815
pubmed: 34077237
J Clin Oncol. 2006 Oct 10;24(29):4692-8
pubmed: 16966684
J Nucl Med. 2007 Dec;48(12):1945-50
pubmed: 18006614
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
J Clin Oncol. 2001 Jan 15;19(2):305-13
pubmed: 11208820
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686